Hudson Bay Capital Management’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Hudson Bay Capital Management’s Portfolio IMNP Stock Details IMNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-64,159	Closed	-$188K	–	606
2017 Q2	$188K	Buy	+64,159	New	+$172K	﹤0.01%	486

Other funds holding IMNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management's IMNP Position: Q3 2017 in Review

Hudson Bay Capital Management sold out of Immune Pharmaceuticals Inc. (IMNP) in Q3 2017, closing a stake of 64,159 shares — an estimated $188K sold.

Hudson Bay Capital Management first reported a position in IMNP in Q2 2017 and held it in 1 quarter. The position peaked at $188K in Q2 2017. 12 funds tracked by Wall St. Rank hold IMNP as of Q3 2017.

Hudson Bay Capital Management reported no remaining Immune Pharmaceuticals Inc. position as of Q3 2017 after selling out during the quarter.
Hudson Bay Capital Management sold 64,159 Immune Pharmaceuticals Inc. shares in Q3 2017, an estimated $188K.
Hudson Bay Capital Management first reported a position in Immune Pharmaceuticals Inc. in Q2 2017 and held it in 1 quarter.
Hudson Bay Capital Management's Immune Pharmaceuticals Inc. position peaked at $188K in Q2 2017.
12 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q3 2017.

Based on Hudson Bay Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.